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Introduction: Accurate prognosis assessment after non–small-cell 
lung cancer (NSCLC) diagnosis is an essential step for making 
effective clinical decisions. This study is aimed to develop a predic-
tion model with routinely available variables to assess prognosis in 
patients with NSCLC in the U.S. Military Health System.
Methods: We used the linked database from the Department of 
Defense’s Central Cancer Registry and the Military Health System 
Data Repository. The data set was randomly and equally split into a 
training set to guide model development and a testing set to validate 
the model prediction. Stepwise Cox regression was used to identify 
predictors of survival. Model performance was assessed by calculating 
area under the receiver operating curves and construction of calibra-
tion plots. A simple risk scoring system was developed to aid quick risk 
score calculation and risk estimation for NSCLC clinical management.
Results: The study subjects were 5054 patients diagnosed with 
NSCLC between 1998 and 2007. Age, sex, tobacco use, tumor 
stage, histology, surgery, chemotherapy, peripheral vascular disease, 
cerebrovascular disease, and diabetes mellitus were identiﬁed as 
signiﬁcant predictors of survival. Calibration showed high agree-
ment between predicted and observed event rates. The area under 
the receiver operating curves reached 0.841, 0.849, 0.848, and 0.838 
during 1, 2, 3, and 5 years, respectively.
Conclusions: This is the ﬁrst NSCLC prognosis model for quick risk 
assessment within the Military Health System. After external valida-
tion, the model can be translated into clinical use both as a web-based 
tool and through mobile applications easily accessible to physicians, 
patients, and researchers.
Key Words: Model, Military health system, Mortality, Non–small-
cell lung cancer, Risk prediction.
(J Thorac Oncol. 2015;10: 1694–1702)
Non–small-cell lung cancer (NSCLC) comprises more than 85% of lung cancers.1 The 5-year survival rates for 
NSCLC range from 58.2% for early-stage disease to a dis-
mal 4.5% for advanced disease.2 Prognosis assessment upon 
NSCLC diagnosis is the ﬁrst essential step toward making 
informed medical care decisions. Currently, cancer stage 
remains the most widely used prognostic factor in risk assess-
ment for NSCLC.3 However, the heterogeneity of the disease 
coupled with comorbidities results in substantial variability in 
survival among patients diagnosed at the same stage.4 A more 
accurate risk stratiﬁcation tool will likely aid in shared clinical 
decision making, designs of clinical trials, and a better alloca-
tion of health-care resources.5
To date, most models are derived from patient popula-
tions of clinical trials with small numbers of patients, con-
ﬁnement to speciﬁc tumor stages, and homogeneous patient 
characteristics.6–12 These models are often aimed at patients 
with advanced stage NSCLC and lack applicability to nonclin-
ical trial patients.13–16 Some models have variables that are not 
readily available in routine clinical practice. In regard to pop-
ulation-based models, Blanchon et al.13 have developed one 
using medical records and questionnaire data from study par-
ticipants diagnosed with NSCLC in French general hospitals. 
This model demonstrated good discrimination accuracy and 
calibration by internal validation. However, the application of 
the model to U.S. populations has not been conducted with 
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an external validation. A recent U.S. based model14 derived 
from the Surveillance, Epidemiology and End Results (SEER) 
database identiﬁed age, sex, tumor grade, tumor stage, and 
race as prognostic factors. However, the clinical application 
of this model is limited by the lack of chemotherapy data. An 
updated version was based on SEER-Medicare population 
and incorporated chronic obstructive pulmonary disease as 
an additional predictor.15 However, the model applies only to 
patients 65 year of age or older.
The U.S. Military Health System (MHS) is an equal 
access health-care system that provides universal health care 
to its beneﬁciaries including military service members, retir-
ees, and their dependents. The Department of Defense (DoD) 
has a Central Cancer Registry (CCR) that collects detailed 
diagnosis, treatment, and follow-up information for patients 
diagnosed with cancer. The DoD also maintains a MHS Data 
Repository (MDR) that contains administrative and medical 
care information for MHS beneﬁciaries. The linked CCR and 
MDR database contains comprehensive data on demographics, 
tumor characteristics, medical history, and treatment informa-
tion for MHS beneﬁciaries,17–21 which offers a unique resource 
to comprehensively study cancer prognosis. So far, there is no 
NSCLC prognosis prediction tool for MHS beneﬁciaries and 
their physicians. The major independent risk factors for pre-
dicting survival among NSCLC patients receiving care from 
the MHS have not been identiﬁed. It is not clear whether risk 
factors identiﬁed from the general population apply to patients 
in the MHS system. Therefore, this study aimed to develop 
a prognostic assessment tool, which can be applied upon the 
diagnosis of NSCLC to the MHS beneﬁciaries, using the data 
in the MHS system.
MATERIALS AND METHODS
Sources of data
Linked data from the DoD’s CCR and the MDR were 
used in this study, as previously described.20,21 Currently, 
the linked database contains the data with cancer diagnosis 
from 1998 to 2007. The CCR contains information for cancer 
patients diagnosed or treated at military treatment facilities, 
including active duty military personnel, retirees, and their 
dependents. The CCR data included demographic variables, 
tumor characteristics, cancer diagnosis, treatment, recurrence, 
and vital status. The registry staff conduct lifetime follow-up 
on patients. Quality assurance was conducted following the 
guidelines established by the North America Association of 
Central Cancer Registries. The MDR contains administra-
tive and medical care information that includes both inpatient 
and outpatient care provided at military treatment facilities 
and civilian facilities paid for by the DoD. The MDR data-
base includes information on clinical diagnoses of all medical 
conditions, which are coded using the diagnostic and treat-
ment procedures or Current Procedural Terminology of the 
International Classiﬁcation of Disease, 9th Revision (ICD-9). 
The Institutional Review Boards of the Walter Reed National 
Military Medical Center, TRICARE Management Activity, 
and the National Institutes of Health Ofﬁce of Human Subjects 
Research approved the data linkage project.
Study Subjects and Variables
A total of 5054 patients diagnosed with histologically 
conﬁrmed primary NSCLC between 1998 and 2007 were 
identiﬁed from the linked database. Cancer site and histol-
ogy were classiﬁed using the topography (C34.0 to C34.3, 
C34.8, C34.9) and morphology codes (8050–8078, 8083, 
8084, 8250–8260, 8480–8490, 8570–8574, 8140, 8211, 8230, 
8231, 8323, 8550, 8551, 8576, 8010–8012, 8014–8031, 8035, 
8310, and any NSCLC codes between 8010 and 8576) of the 
International Classiﬁcation of Diseases for Oncology, third 
edition (ICD-O-3).22
Demographic variables, tobacco use history, and tumor 
characteristics were obtained from the CCR. Demographic 
variables included age, sex, race, marital status, active duty 
status, and military service branch of patient or sponsor at 
the time of diagnosis. Tumor characteristics included tumor 
stage, histology, and tumor recurrence. Comorbidity data 
were obtained from the MDR. Comorbidities were con-
sidered as present if a diagnosis was recorded in at least 
one inpatient record or three or more outpatient records. 
Comorbidities were included if diagnosed at or before the 
diagnosis of NSCLC. Vital status and date of death were 
obtained from CCR. Both CCR and MDR data were used to 
determine the receipt of surgery, chemotherapy, and radiation 
therapy. Missing values in a variable were coded as a separate 
missing/unknown category.
Statistical Analyses
The survival time was calculated as the difference 
between date of diagnosis and date of death or censored at 
the date of last contact or the end of the study, December 
31, 2009. The data set was randomly and equally split into 
a training set (50% of the data) to guide the building of 
the risk model and a testing set (the remaining 50% of the 
data) to validate the model prediction. Model development 
was performed in both the training and further repeated 
using the full data set. As the results were similar, only 
results from the full data set are presented in the final 
model. The assessment of model discriminatory accuracy 
and calibration was performed in training, testing, and the 
full datasets.
We ﬁrst performed univariate Cox regression to assess 
the association between individual variables and death. 
Variables with statistical signiﬁcance (p < 0.05) and clinical 
relevance were considered as candidates for stepwise Cox 
regression analysis. Stepwise Cox regression was performed 
to choose the ﬁnal subset of predictors. The model’s discrimi-
natory accuracy for predicting mortality was assessed by 
constructing the time-dependent receiver operating character-
istic curves for censored survival data23 and calculated area 
under curve (AUC). We assessed model calibration capability 
by assessing the agreement between predicted and observed 
death rates.24
To facilitate the utility of the models in the clinical set-
ting, we derived risk scores based on regression coefﬁcients 
in the Cox proportional hazards model following standard 
procedures.25 The risk score was calculated by dividing each 
regression coefﬁcient by the smallest coefﬁcient signiﬁcantly 
1696 Copyright © 2015 by the International Association for the Study of Lung Cancer
Lin et al. Journal of Thoracic Oncology ® • Volume 10, Number 12, December 2015
different from 0, and then rounding that number to the nearest 
integer. The lowest category of each risk factor was assigned a 
score of 0. Total risk score was calculated for each patient by 
summing the scores from all risk factors.
We calculated the individualized risk of death from 
baseline probability (probability of death at the reference level 
of all risk factors) and relative risk estimated from the Cox 
regression model. The predicted risks of death were estimated 
using the following equation26:
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TABLE 1. Predictors of Mortality Among Non–Small-Cell Lung Cancer Patients Diagnosed Between 1998 and 2007 in the 
Military Health System
Risk Factors
Regression  
Coefficient (β)
Standard 
Error
Hazard 
Ratio
95% Confidence 
Interval P Value
Age (yr)
  <50 0.000 0.000 Ref. Ref.
  50–59 0.037 0.082 1.037 0.883–1.218 0.6543
  60–69 0.149 0.077 1.161 0.998–1.350 0.053
  70–74 0.170 0.085 1.185 1.003–1.399 0.0454
  75–79 0.190 0.090 1.209 1.013–1.443 0.0353
  80 and older 0.245 0.097 1.278 1.056–1.545 0.0116
Sex
  Female 0.000 0.000 Ref. Ref.
  Male 0.163 0.040 1.177 1.088–1.272 <0.0001
Tobacco use history
  Never used 0.000 0.000 Ref. Ref.
  Previous use 0.207 0.078 1.230 1.055–1.435 0.0083
  Current use 0.315 0.080 1.371 1.173–1.602 <0.0001
Stage
  IA 0.000 0.000 Ref. Ref.
  IB 0.344 0.079 1.410 1.208–1.647 <0.0001
  IIA 0.537 0.134 1.710 1.316–2.222 <0.0001
  IIB 0.761 0.094 2.141 1.782–2.571 <0.0001
  IIIA 0.982 0.080 2.670 2.284–3.121 <0.0001
  IIIB 1.183 0.079 3.265 2.799–3.808 <0.0001
  IV 1.658 0.072 5.247 4.560–6.038 <0.0001
Histology
  Squamous cell carcinoma 0.000 0.000 Ref. Ref.
  Adenocarcinoma 0.015 0.047 1.016 0.927–1.113 0.7408
  Large-cell carcinoma 0.255 0.065 1.290 1.136–1.465 <0.0001
  Other NSCLC, NOS 0.028 0.055 1.028 0.924–1.144 0.6128
Surgery
  Yes 0.000 0.000 Ref. Ref.
  No 1.010 0.049 2.746 2.493–3.024 <0.0001
Chemotherapy
  Yes 0.000 0.000 Ref. Ref.
  No 0.574 0.042 1.775 1.635–1.926 <0.0001
Peripheral vascular disease
  No 0.000 0.000 Ref. Ref.
  Yes 0.153 0.058 1.165 1.039–1.306 0.0091
Cerebrovascular disease
  No 0.000 0.000 Ref. Ref.
  Yes 0.170 0.065 1.185 1.043–1.346 0.0092
Type II diabetes mellitus
  No 0.000 0.000 Ref. Ref.
  Yes 0.117 0.047 1.124 1.024–1.234 0.014
NSCLC, non–small-cell lung cancer; NOS, not otherwise speciﬁed.
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where F(t) denotes the probability of death in t years 
given covariates X (x
1
 to x
p
). M
j
 denotes the mean level of 
X
j
. S(t) denotes the probability of alive until t; S
0
(t) denotes 
the baseline survival function; and b
j
 denotes the regression 
coefﬁcients.
Statistical analyses were conducted using the SAS soft-
ware version 9.3.0 (SAS Institute, Inc., Cary, NC) and the R 
software. All reported p values are two sided, with the signiﬁ-
cance level set at p < 0.05.
RESULTS
Among the 5054 patients, 3504 died during the fol-
low-up period. The distributions of patient characteris-
tics by vital status are shown in Supplementary Table 1 
(Supplementary Digital Content, http://links.lww.com/JTO/
A907). After stepwise selection, as shown in Table 1, the ﬁnal 
multivariate model shows a signiﬁcant increase in mortality 
associated with older age (age 70–74 versus age <50: hazard ratio 
[HR] = 1.185, 95% CI = 1.003–1.399; age 75–79 versus age 
<50: HR = 1.209, 95% CI = 1.013–1.443; age 80 and older 
versus age <50: HR = 1.278, 95% CI = 1.056–1.545), male gen-
der (male versus female: HR = 1.177, 95% CI = 1.088–1.272), 
tobacco use (previous use versus never use: HR = 1.230, 95% 
CI = 1.055–1.435; current use versus never use: HR = 1.371, 
95% CI = 1.173–1.602), late tumor stage (IB versus IA: 
HR = 1.410, 95% CI = 1.208–1.647; IIA versus IA: 
HR = 1.710, 95% CI = 1.316–2.222; IIB versus IA: HR = 2.141, 95% 
CI = 1.782–2.571; IIIA versus IA: HR = 2.670, 95% 
CI = 2.284–3.121; IIIB versus IA: HR = 3.265, 95% 
CI = 2.799–3.808; IV versus IA: HR = 5.247, 95% CI = 4.560–
6.038), large-cell histology (large-cell carcinoma versus squa-
mous cell carcinoma: HR = 1.290, 95% CI = 1.136–1.465), 
no surgery (no versus yes: HR = 2.746, 95% CI = 2.493–
3.024), no chemotherapy (no versus yes: HR = 1.775, 95% 
CI = 1.635–1.926), peripheral vascular disease (yes versus no; 
fIGURE 1. Calibration plots (observed probability versus predicted probability) for different time periods: (A) 1 year;  
(B) 2 years; (C) 3 years; (D) 5 years. Y-axis represents observed probability. X-axis represents predicted probability. The predicted 
and observed probabilities of survival are graphed on the horizontal and vertical axes, respectively. The grey line indicates the 
reference line, on which an ideal model would lie. Solid dots indicate the predictions; X’s indicate the cross-validated predic-
tions. Vertical bars indicate 95% confidence intervals around the prediction.
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HR = 1.165, 95% CI = 1.039–1.306), cerebrovascular disease 
(yes versus no; HR = 1.185, 95% CI = 1.043–1.346), and diabe-
tes mellitus (yes versus no; HR = 1.124, 95% CI = 1.024–1.234).
The calibration plot showed that the observed prob-
abilities of survival were all within the 95% CI of the pre-
dicted probabilities of survival at 2, 3 and 5 years after 
diagnosis (Fig. 1B, C and D, respectively). The model 
slightly underestimated survival among individuals having 
survival probability greater than 0.8 in the ﬁrst year after 
diagnosis (Fig. 1A).
Figure 2 shows that the AUC reached 0.841 (A), 0.849 
(B), 0.848 (C), and 0.838 (D) for 1-, 2-, 3-, and 5-year predic-
tion, respectively. The AUCs were similar in the full, train-
ing, and testing data sets (Table 2). For example, the AUCs for 
predicting survival in 2 years were 0.849 (95% CI = 0.829–
0.864), 0.848 (95% CI = 0.830–0.864), and 0.849 (95% 
CI = 0.835–0.862) for the full, training, and testing data sets, 
respectively.
Risk scores were assigned to each signiﬁcant risk 
factor identiﬁed in the model (Supplementary Table 2, 
Supplementary Digital Content, http://links.lww.com/JTO/
A907). Probability of survival decreased in all risk groups 
over time after diagnosis. Given a time point, patients with 
a higher risk score exhibited lower survival probability than 
patients with a lower risk score (Fig. 3).
We next applied the model to predict probability of sur-
vival using ﬁve hypothetical examples (Table 3). Example 1 
is a 71-year-old man with stage IB squamous cell carcinoma, 
a current smoker with a history of cerebrovascular disease 
and diabetes. The patient has refused to receive surgery. The 
total risk score for this patient is then 23, and the predicted 
probability of survival in 1 year is 0.458 (95% CI = 0.386–
0.543). If the same patient is treated with surgery (example 
2), then his total risk score decreases to 15, and 1-year sur-
vival probability is signiﬁcantly increased to 0.752 (95% 
CI = 0.709–0.799). The risk score decreases to 13, and the 
1-year survival probability is further increased to 0.826 (95% 
CI = 0.800–0.852), as shown in example 3, provided that the 
patient had stopped smoking and become a former smoker 
(e.g., had stopped smoking for at least a year or more) and had 
fIGURE 2. Time-dependent receiver operating characteristic curves and area under curve for different time periods: (A) 1 year; 
(B) 2 years; (C) 3 years; (D) 5 years.
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not had comorbidities. In example 4, the patient is a 66-year-
old woman with adenocarcinoma diagnosed at stage IIIB, a 
never smoker with a history of peripheral vascular disease. 
The total risk score is 25, and the predicted probability of sur-
vival in 1 year is 0.377 (95% CI = 0.302–0.471). If she does 
not have a history of peripheral vascular disease and is willing 
to undergo chemotherapy, as shown in example 5, then the risk 
score decreases to 16 and her survival probability increases to 
0.624 (95% CI = 0.571–0.682). The predictions in 2, 3, and 
5 years under these hypothetical scenarios are also shown in 
Table 3.
DISCUSSION
Accurate prognostic assessment tool is important to 
guide shared treatment decision making and disease man-
agement. In building risk prediction tools, one important 
consideration is the tradeoff between statistical accuracy 
and clinical utility. The more predictors a model includes, 
the more accurate the prediction could be. However, the 
unavailability of the many predictors in routine clinical set-
tings could damper the model’s clinical utility. Although a 
simple model with a few predictors could be statistically 
less accurate than a model that exhausts all possible pre-
dictors, it has higher clinical utility with readily available 
variables from a clinical setting. It is ideal to have a simple 
model based on routinely available predictors while achiev-
ing high prediction accuracy.
Our model was based on variables from routine medi-
cal care settings and generated high prediction accuracy and 
calibration with a discrimination accuracy of 84% to 85%. In 
clinical settings, besides tumor stage and histology informa-
tion usually obtained from routine diagnosis workout, a par-
ticular patient will only need to provide simple information 
on demographics (age and sex), tobacco use history (never, 
previous or current), diagnosis of a few comorbidities (yes or 
no), and prior cancer treatment (yes or no) to have risk score 
calculated and probability of survival accurately estimated.
Unlike the few previous published tools that used clini-
cal trial participants,6–12,27,28 our utility comes from taking real-
world known outcomes and developing a tool within the closed 
MHS. Patients enrolled in speciﬁc clinical trials are mostly a 
homogeneous group with deﬁned characteristics (e.g., certain 
stage and age groups) to satisfy eligibility criteria of the trials. 
These models are, therefore, not generalizable to other popu-
lations. Moreover, the homogeneity of treatment regimens and 
agents in certain clinical trials makes these models trial-spe-
ciﬁc and less suitable for general clinical use. Some of these 
models also require data from additional procedures that are 
not readily available during the initial clinic visit.7–10 Although 
TABLE 2. Time-Dependent AUC of the Prediction Model 
in Training, Testing, and Full Data Sets for Non–Small-Cell 
Lung Cancer Patients Diagnosed Between 1998 and 2007 in 
Military Health System
AUC 95% CI
In 1 yr
  Training set 0.840 0.823–0.857
  Testing set 0.842 0.826–0.860
  Full data set 0.841 0.829–0.853
In 2 yr
  Training set 0.849 0.829–0.864
  Testing set 0.848 0.830–0.864
  Full data set 0.849 0.835–0.859
In 3 yr
  Training set 0.849 0.832–0.869
  Testing set 0.851 0.831–0.868
  Full data set 0.848 0.835–0.862
In 5 yr
  Training set 0.843 0.812–0.862
  Testing set 0.840 0.822–0.865
  Full data set 0.838 0.822–0.854
AUC, area under curve; CI, conﬁdence interval.
fIGURE 3. Survival probability by risk score 
groups. Risk scores were assigned to each risk 
factor by dividing each regression coefficient 
by the smallest coefficient significantly different 
from 0, and then rounded to the nearest integer. 
A risk score was assigned to each patient by 
summing the points for each risk factor present. 
Risk score groups are defined as following: group 
1: risk score = 0 to 9; group 2: risk score = 10 to 
14; group 3: risk score = 15 to 19; group 4: risk 
score = 20 to 24; group 5: risk score = 25 to 29; 
group 6: risk score ≥ 30.
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external validation of these models has been performed, the 
number of patients, both in the development and validation 
cohorts, is still relatively small.7,8,10 Our model was derived 
from larger patient population with the rich epidemiologic 
and medical care data and can be applied to a wider range of 
patient population.
Currently, there are few population-based models 
with a wide range of patient population. A French study13 
developed a prognostic model that identiﬁed age, sex, per-
formance status at diagnosis, histological type, and tumor 
stage as independent predictors of mortality with good 
calibration and a high discrimination accuracy. However, 
therapeutic treatments were not considered as candidate 
variables in model development, and tobacco use history 
was not identiﬁed to affect survival in the French popula-
tion. Among studies from U.S. populations, a study based on 
the National Cancer Institute’s SEER data14 identiﬁed age, 
sex, tumor grade, tumor stage, and race as prognostic fac-
tors. This model had a much lower discriminatory accuracy 
of 0.73.14 Because of the lack of chemotherapy and comor-
bidity data in the SEER database, the prognostic signiﬁcance 
of treatment and comorbidity could not be assessed. An 
update of this model was derived from the SEER-Medicare 
data.15 However, because SEER-Medicare data contain only 
patients of 65 years or older, the model cannot apply to 
younger patients.
Unlike the SEER and the SEER-Medicare based model, 
our model covers all ages and has the capacity to assess treat-
ment effects and thus is able to aid both clinical decision 
making and shared decision making. It is noteworthy that 
race was not identiﬁed as a signiﬁcant predictor of survival in 
our population, whereas both the SEER and SEER-Medicare 
models14,15 identiﬁed black race to be associated with an 
increased risk of mortality. This is most probably a result of 
all our patients being treated in an equal health-care system 
regardless of race.29
Although our model was developed within the MHS sys-
tem, the factors identiﬁed are consistent with those identiﬁed 
in the general population. All variables included in our model 
have high clinical relevance to survival in NSCLC patients. 
Speciﬁcally, advanced tumor stage, older age, male sex, and 
tobacco use are well-established risk factors associated with 
poor survival in NSCLC patients.30,31 Large-cell histology 
has also been reported to be associated with worse survival 
compared with other histologic types.12,14 The associations 
between type II diabetes mellitus and high risk of mortality 
in lung cancer patients have been reported in previous stud-
ies,32–35 although the association was not consistently observed 
in other studies.36 Peripheral vascular and cerebrovascular dis-
eases are among the most usually found comorbidities among 
lung cancer patients who contributed to decreased survival 
in NSCLC patients.37,38 Our results showed that the associa-
tions of the comorbidities with survival remain signiﬁcant 
in the presence of strong predictors such as tumor stage and 
treatments. Although these comorbid conditions may not be 
completely curable, the results suggest the importance of bet-
ter management and treatment of the comorbid conditions to 
improve survivorship while receiving cancer treatments. Our 
results also suggest the potential role of tobacco cessation for 
improving survival.
This study can be further improved. First, progress in 
molecular markers has made it possible to integrate molecular 
proﬁles4,39–41 convenient in clinical use, such as the epidermal 
growth factor receptor, a well-established marker influencing 
TABLE 3. Application of the Prediction Model to Hypothetical Individuals With Different Risk Profiles
Example 1 Example 2 Example 3 Example 4 Example 5
Age (yr) 71 71 71 66 66
Sex Male Male Male Female Female
Tobacco use Current Current Previous Never Never
Stage IB IB IB IIIB IIIB
Histology Squamous cell  
carcinoma
Squamous cell  
carcinoma
Squamous cell  
carcinoma
Adenocarcinoma Adenocarcinoma
Peripheral vascular disease No No No Yes No
Cerebrovascular disease Yes Yes No No No
Type II diabetes mellitus Yes Yes No No No
Surgery No Yes Yes No No
Chemotherapy No No No No Yes
Total risk score 23 15 13 25 16
Predicted probability of 
survival in 1 yr (95% CI)
0.458 (0.386–0.543) 0.752 (0.709–0.799) 0.826 (0.800–0.852) 0.377 (0.302–0.471) 0.624 (0.571–0.682)
Predicted probability of 
survival in 2 yr (95% CI)
0.219 (0.158–0.305) 0.576 (0.513–0.645) 0.689 (0.649–0.731) 0.150 (0.097–0.232) 0.400 (0.337–0.475)
Predicted probability of 
survival in 3 yr (95% CI)
0.105 (0.064–0.171) 0.439 (0.371–0.521) 0.575 (0.536–0.627) 0.060 (0.031–0.114) 0.256 (0.198–0.330)
Predicted probability of 
survival in 5 yr (95% CI)
0.033 (0.016–0.071) 0.289 (0.223–0.375) 0.434 (0.380–0.495) 0.014 (0.005–0.038) 0.128 (0.086–0.189)
CI, conﬁdence interval.
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treatment response and outcome in NSCLC patients.42 The 
integration of clinical molecular markers into our model is 
warranted and is planned as they become available. Second, 
performance status, which was not available in our study, may 
be a potential prognostic factor to be tested and integrated 
into the model if it helps improve model prediction. Third, 
there have been advances in lung cancer diagnosis, staging, 
and treatment during the time covered in this study and since. 
The introduction of positron emission tomography and endo-
bronchial ultrasound aids diagnosis and staging. The ability to 
provide targeted therapy has improved the treatment armamen-
tarium. Thus, this model could be further tested and improved 
with the inclusion of current standards of care. Finally, exter-
nal validation of our model in the general population would 
be desirable. Although our results are similar to some previ-
ous studies in the general population, the model may not be 
directly generalized to the general population without external 
validation.
In conclusion, our model is the ﬁrst NSCLC progno-
sis model for the DoD’s MHS system that could help physi-
cians and patients perform quick prognosis assessment. The 
model prediction has high statistical accuracy, and the vari-
ables are readily obtainable in routine clinical setting. The 
risk scores are simple to calculate and allow for ease in com-
munication. After external validation, the model can be trans-
lated into clinical use as a web-based tool or through portable 
mobile devices easily accessible to physicians, patients, and 
researchers.16,43
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Erratum
Identifying Targeted Strategies to Improve Smoking Cessation Support for Cancer Patients: Erratum
An error appeared in the degree listed for one of the authors of the article that appeared on page 1532 of the November 2015 issue of the Journal.
The author’s name should have appeared as Shiva Dibaj, MS.
The authors regret this error.
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